Q2053 – Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
HCPCS Level II code · Q codes: Temporary Codes
HCPCS codeQ2053
- Long description
- Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Short description
- Brexucabtagene car pos t
- Pricing indicator
51Drugs- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1EOther drugs- Added
- April 1, 2021
- Last change
- April 1, 2021 – No change
Frequently asked questions
What is HCPCS code Q2053?
Q2053 is a HCPCS Level II code for brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.
Does Medicare cover Q2053?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby Q codes
- Q2039 – Influenza virus vaccine, not otherwise specified
- Q2040 – Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
- Q2041 – Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2042 – Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2043 – Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion
- Q2049 – Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg
- Q2050 – Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
- Q2052 – Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)
- Q2054 – Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2055 – Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2056 – Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2057 – Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2058 – Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
- Q3001 – Radioelements for brachytherapy, any type, each
- Q3014 – Telehealth originating site facility fee
- Q3027 – Injection, interferon beta-1a, 1 mcg for intramuscular use
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.